Drug Profile
Research programme: anticancer immunoconjugates - Traws Pharma
Alternative Names: ON-013100; ON-01500Latest Information Update: 04 Apr 2024
Price :
$50
*
At a glance
- Originator Onconova Therapeutics
- Developer Traws Pharma
- Class Small molecules; Sulfones
- Mechanism of Action Cell cycle inhibitors; Signal transducing adaptor protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 02 Apr 2024 Trawsfynydd Therapeutics has merged with Onconova Therapeutics to form Traws Pharma
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 21 Apr 2015 Pharmacodynamics data from preclinical studies in Cancer presented at the Annual Meeting of American Association of Cancer Research (AACR-2015)